– Plan to supply ‘AccuraDtect,’ the COVID-19 test kit with CE-IVD certification acquired from Europe to Indonesia
– Enable to produce results within 4 hours after sample collection…Expecting to strengthen responsiveness to COVID-19
Daewoong Pharmaceutical Company Indonesia (hereinafter referred to as DPCI) (CEO Sengho Jeon) that is developing COVID-19 treatment announced on 22th that it acquired a license to sell ‘AccuraDtect’ SARS-COV-2 RT-qPCR Kit, a molecular test kit for COVID-19 in Indonesia.
“As the spread of COVID-19 in Indonesia becomes more severe, the demand for COVID-19 test kits in every country is increasing rapidly,” said Sengho Jeon, CEO of DPCI. “With this approval for sale, we expect that the supply of the test kit can contribute greatly to improving Indonesia’s responsiveness to overcome COVID-19 pandemic by supplying Korea’s excellent PCR (Polymerase Chain Reaction),” he stated.
‘AccuraDtect’ is a highly sensitive COVID-19 molecular test kit that targets the leader sequence found most in infected cells in addition to the N2 gene, which is usually detected for COVID-19, to diagnose whether an individual is infected with the virus.
Under the standards recommended by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) in the United States, AccuraDtect targets three biomarkers, which can identify the presence of coronavirus, RdRp, E and N2 and enables to produce results within 4 hours after sample collection.
In particular, it is designed to measure even Ribonuclease (RNase) P, which can determine the suitability of the sample and act as an infection spreader in the infected cells of virus. Furthermore, as it uses the gene amplification technique called real-time polymerase chain reaction (RT-qPCR) to amplify and detect virus genes, it has a high level of accuracy (including sensitivity and specificity).
This kit has obtained CE-IVD from Europe last March and emergency use authorization from Peru and Singapore.
Regarding this supply license, CEO Sengho Jeon at DPCI said, “We are planning to do our best effort to provide a total solution to overcome COVID-19 pandemic while successfully developing COVID-19 drugs niclosamide and chamostat, which are currently under development.”
Meanwhile, Daewoong Pharmaceutical Indonesia plans to quickly secure a local partner who will be responsible for the distribution of ‘AccuraDtect’ and supply it to Indonesia. ‘AccuraDtect’, a test kit for COVID-19, is the original developer of Genomictree, a Korean company specializing in developing non-invasive molecular diagnostics for the early detection of cancers based on the biomarker and Daewoong Pharmaceutical owns the global distributorship.